Financials

  • Market Capitalization 51.85 B
  • Employee 16 K
  • Founded N/A
  • CEO -
  • Website www.edwards.com
  • Headquarter Delaware, United States
  • FIGI BBG000BRXP69
  • Industry Medical Devices
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
46.58
Price to sales ratio
8.26

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
135
MDT
Medtronic plc. Ordinary Shares
89.98 USD-2.22%-2.15%+3.76%-4.10%115.18 B USD
252
BSX
Boston Scientific Corporation Common Stock
46.65 USD-3.16%-4.95%+9.10%-55.77%67.61 B USD
349
MDLN
Medline Inc. - Class A common stock
34.65 USD+0.20%+6.58%-14.19%-1.00%45.55 B USD
432
DXCM
DexCom, Inc. - Common Stock
89.29 USD+0.37%-0.36%+19.98%+18.93%33.69 B USD

Frequently asked questions about Edwards Lifesciences Corp

What is the Edwards Lifesciences Corp stock price today?

The current price of Edwards Lifesciences Corp (EW) is 89.95. Over the past 24 hours, the stock has changed by -0.90%. Follow the EW chart for real-time price dynamics.

What is the stock ticker of Edwards Lifesciences Corp?

Edwards Lifesciences Corp trades under the ticker EW. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Edwards Lifesciences Corp stock going up?

EW has changed by +0.13% over the last week, +6.35% over the last month, and +10.73% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Edwards Lifesciences Corp?

Edwards Lifesciences Corp currently has a market capitalization of 51.85 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Edwards Lifesciences Corp earnings last quarter?

Last quarter, Edwards Lifesciences Corp reported earnings of 0.42 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Edwards Lifesciences Corp revenue for the last quarter?

Edwards Lifesciences Corp reported quarterly revenue of 1.77 B. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Edwards Lifesciences Corp net income for the last quarter?

Edwards Lifesciences Corp reported net income of 241.9 M for the last quarter. The previous quarter showed 380.7 M, which means net income changed by -36.46%.

How many employees does Edwards Lifesciences Corp have?

As of the latest available data, Edwards Lifesciences Corp has 16 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Edwards Lifesciences Corp EBITDA?

Edwards Lifesciences Corp EBITDA is 574.9 M, and its EBITDA margin is 32.46%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Edwards Lifesciences Corp stock?

You can buy Edwards Lifesciences Corp (EW) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Edwards Lifesciences Corp stock?

Investing in Edwards Lifesciences Corp requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the EW chart and related analysis on metatrader.com as part of your research.

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.

News